Overview
Adelphi Real World provides real world evidence by running Disease Specific Programmes (DSPs), tailored non-interventional studies, and international secondary database analyses to generate insights from physicians, patients, caregivers, and payers. Its work collects data across Europe, the USA, Asia, and Latin America to inform activities across the brand lifecycle, including health outcomes, medical affairs, market access, and marketing communications. The company combines DSPs and Bespoke solutions to deliver end-to-end evidence that covers the full lifecycle of a medical product and helps shape both multi-country strategies and domestic execution. Its goal is to provide actionable real-world evidence that supports decision-making and improves outcomes throughout a product’s lifecycle.
Work here?Claim your company
Simplify's Take
What believers are saying
- Revelio estimates headcount at 280 in March 2026, up 11.4% since 2023.
- Adelphi launched 2026 content on respiratory, metabolic, neurology, and cardiovascular research.
- The company updated its website on October 5, 2026, indicating active commercial maintenance.
What critics are saying
- 2026 active job postings fell to one, showing hiring momentum collapsed.
- Private consultancies face client concentration; one pharma budget cut can crush revenue quickly.
- If sponsors shift to internal AI analytics, Adelphi's DSP model gets commoditized by 2027.
What makes Adelphi Real World unique
- Adelphi Real World runs disease-specific programmes across 20+ specialties, from oncology to rare disease.
- Its 2026 conference slate spans ECCO, AAD, ASCO, ESMO, and ISPOR, signaling client access.
- The firm publishes DSP-based evidence from 1,131 HAE patients across U.S., Europe, Japan.
Help us improve and share your feedback! Did you find this helpful?